MEROLA, J.; SOFEN, H.; THACI, D.; PAUL, C.; IMAFUKU, S.; BANERJEE, . S.; ARMSTRONG , A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy Analysis by Baseline Disease Characteristics From the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s36, 2021. DOI: 10.25251/skin.5.supp.36. Disponível em: Acesso em: 18 may. 2022.